Randomized trial · people

Tesamorelin: 15.2% drop in visceral fat at 26 weeks in HIV

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with HIV and belly fat buildup, 26 weeks of tesamorelin cut visceral fat and improved blood fats compared with placebo, with no significant change in glucose or insulin.

Kind
Randomized trial
Studied in
People
Number studied
412
Published
2007
Journal
N Engl J Med

What they tested

The team tested whether daily tesamorelin could reduce visceral fat (deep belly fat around the organs) in people with HIV who had built up abdominal fat.

How the study was done

A randomized, placebo-controlled trial at multiple centers in 412 people with HIV and extra abdominal fat, 86% of them men. They got a daily shot under the skin of either 2 mg of tesamorelin or placebo (a dummy shot) for 26 weeks, with visceral fat measured by CT scan.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Visceral fat fell by 15.2% in the tesamorelin group and rose by 5.0% in the placebo group. Triglycerides (a blood fat) dropped by 50 mg per deciliter on tesamorelin and rose by 9 mg per deciliter on placebo, and the ratio of total cholesterol to HDL cholesterol fell by 0.31 versus a rise of 0.21 (P<0.001 for all). IGF-I, a growth hormone marker, rose by 81.0% on tesamorelin and fell by 5.0% on placebo, and total and HDL cholesterol also improved on tesamorelin. Glucose and insulin did not differ significantly between groups, and overall side effects were similar, though more people on tesamorelin dropped out because of a side effect.

What it doesn’t show

The trial lasted 26 weeks and enrolled mostly men with HIV and abdominal fat buildup, so it does not show longer-term effects or results in other groups. It measured fat and blood markers, not heart attacks or other heart outcomes.

The paper

Falutz et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007.

The compound

More studies on Tesamorelin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo